Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): Study protocol for a randomized controlled trial

and for the SABATO trial group (with linked authorship to the individuals in the Acknowledgements section), Achim J. Kaasch*, Gerd Fätkenheuer, Reinhild Prinz-Langenohl, Ursula Paulus, Martin Hellmich, Verena Weiß, Norma Jung, Siegbert Rieg, Winfried V. Kern, Harald Seifert, Karl Lewalter, Sebastian Lemmen, Cornelis Stijnis, Jan Van der Meer, Alex Soriano, Laura Morata Ruiz, Keikawus Arastéh, Hartmut Stocker, Jan KluytmansJacobien Veenemans, Hans Reinhard Brodt, Christoph Stephan, Timo Wolf, Johanna Kessel, Insa Joost, Bhanu Sinha, Sander van Assen, Kasper Wilting, Welte Tobias Welte, Mölgen Christiane Mölgen, Freise Julia Freise, Frank Brunkhorst, Mathias Pletz, Stefan Hagel, Christian Becker, Thomas Frieling, Katrin Kösters, Stefan Reuter, Mikai Hsiao, Jan Rupp, Mathias Pletz, David Turner, Susan Snape, Shanika Crusz, Pradhib Venkatesan, Bernd Salzberger, Frank Hanses, Jesùs Rodriguez-Baño, Adoración Valiente Méndez, Luis Eduardo López-Cortés

*Corresponding author for this work
5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): Study protocol for a randomized controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences